Immune landscape and response to oncolytic virus-based immunotherapy.

IF 3.9 3区医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL Frontiers of Medicine Pub Date : 2024-06-01 Epub Date: 2024-03-08 DOI:10.1007/s11684-023-1048-0

Chaolong Lin, Wenzhong Teng, Yang Tian, Shaopeng Li, Ningshao Xia, Chenghao Huang

{"title":"Immune landscape and response to oncolytic virus-based immunotherapy.","authors":"Chaolong Lin, Wenzhong Teng, Yang Tian, Shaopeng Li, Ningshao Xia, Chenghao Huang","doi":"10.1007/s11684-023-1048-0","DOIUrl":null,"url":null,"abstract":"<p><p>Oncolytic virus (OV)-based immunotherapy has emerged as a promising strategy for cancer treatment, offering a unique potential to selectively target malignant cells while sparing normal tissues. However, the immunosuppressive nature of tumor microenvironment (TME) poses a substantial hurdle to the development of OVs as effective immunotherapeutic agents, as it restricts the activation and recruitment of immune cells. This review elucidates the potential of OV-based immunotherapy in modulating the immune landscape within the TME to overcome immune resistance and enhance antitumor immune responses. We examine the role of OVs in targeting specific immune cell populations, including dendritic cells, T cells, natural killer cells, and macrophages, and their ability to alter the TME by inhibiting angiogenesis and reducing tumor fibrosis. Additionally, we explore strategies to optimize OV-based drug delivery and improve the efficiency of OV-mediated immunotherapy. In conclusion, this review offers a concise and comprehensive synopsis of the current status and future prospects of OV-based immunotherapy, underscoring its remarkable potential as an effective immunotherapeutic agent for cancer treatment.</p>","PeriodicalId":12558,"journal":{"name":"Frontiers of Medicine","volume":null,"pages":null},"PeriodicalIF":3.9000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers of Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11684-023-1048-0","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/8 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Oncolytic virus (OV)-based immunotherapy has emerged as a promising strategy for cancer treatment, offering a unique potential to selectively target malignant cells while sparing normal tissues. However, the immunosuppressive nature of tumor microenvironment (TME) poses a substantial hurdle to the development of OVs as effective immunotherapeutic agents, as it restricts the activation and recruitment of immune cells. This review elucidates the potential of OV-based immunotherapy in modulating the immune landscape within the TME to overcome immune resistance and enhance antitumor immune responses. We examine the role of OVs in targeting specific immune cell populations, including dendritic cells, T cells, natural killer cells, and macrophages, and their ability to alter the TME by inhibiting angiogenesis and reducing tumor fibrosis. Additionally, we explore strategies to optimize OV-based drug delivery and improve the efficiency of OV-mediated immunotherapy. In conclusion, this review offers a concise and comprehensive synopsis of the current status and future prospects of OV-based immunotherapy, underscoring its remarkable potential as an effective immunotherapeutic agent for cancer treatment.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

免疫格局和对基于溶瘤病毒的免疫疗法的反应。

基于肿瘤溶解病毒（OV）的免疫疗法已成为一种前景广阔的癌症治疗策略，它具有选择性靶向恶性细胞、同时保护正常组织的独特潜力。然而，肿瘤微环境（TME）的免疫抑制特性限制了免疫细胞的活化和招募，这对将溶瘤病毒开发成有效的免疫治疗药物构成了巨大障碍。本综述阐明了基于 OV 的免疫疗法在调节 TME 内免疫环境以克服免疫耐受和增强抗肿瘤免疫反应方面的潜力。我们研究了 OV 在靶向特定免疫细胞群（包括树突状细胞、T 细胞、自然杀伤细胞和巨噬细胞）方面的作用，以及它们通过抑制血管生成和减少肿瘤纤维化来改变 TME 的能力。此外，我们还探讨了优化基于 OV 的药物输送和提高 OV 介导的免疫疗法效率的策略。总之，这篇综述简明而全面地概述了基于 OV 的免疫疗法的现状和未来前景，强调了它作为一种有效的癌症免疫治疗药物的巨大潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Frontiers of Medicine ONCOLOGYMEDICINE, RESEARCH & EXPERIMENTAL&-MEDICINE, RESEARCH & EXPERIMENTAL

CiteScore

18.30

自引率

0.00%

发文量

800

期刊介绍： Frontiers of Medicine is an international general medical journal sponsored by the Ministry of Education of China. The journal is jointly published by the Higher Education Press and Springer. Since the first issue of 2010, this journal has been indexed in PubMed/MEDLINE. Frontiers of Medicine is dedicated to publishing original research and review articles on the latest advances in clinical and basic medicine with a focus on epidemiology, traditional Chinese medicine, translational research, healthcare, public health and health policies.